Results 61 to 70 of about 12,625 (176)

IvanAuHKU/COVID-nirmatrelvir-ritonavir-pediatric: Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation

<p>Analysis code for the study "Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation"</p ...
IvanAuHKU
core   +1 more source

Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study

BMC Infectious Diseases
Background and aim Two oral antivirals (Nirmatrelvir- ritonavir and Azvudine) are widely used in China practice during the Omicron wave of the pandemic.
Xiaobo Han, Darui Gao, Chenglong Li, Xin Yuan, Junchang Cui, Weiguo Zhao, Fei Xie, Kaifei Wang, Yuhong Liu, Guoxin Muo, Na Xi, Mengli Zheng, Rentao Wang, Kun Xiao, Dahui Zhao, Xinxin Zhang, Xinjie Han, Bo Wang, Tiantian Zhang, Wuxiang Xie, Lixin Xie   +20 more
doaj   +1 more source

Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications

Israel Journal of Chemistry, Volume 66, Issue 3, May 2026.
The picture depicts the molecules discussed in the review. On the left side, the general scaffold of sugars is shown. Next to it are four carbohydrate‐based molecules, including remdesivir, islatravir, empagliflozin, and Globo‐H. Remdesivir and islatravir contain a substituted ribose ring attached to a modified nucleobase.
Stephan Scheeff, Jemma Arakelyan, Billy Wai‐Lung Ng   +2 more
wiley   +1 more source

Image_1_Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?.pdf

, 2022
BackgroundThe impact of nirmatrelvir/ritonavir treatment on shedding of viable virus in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unclear.MethodsA prospective cohort study evaluating mildly ill COVID-19 patients was conducted ...
Doo Ryeon Chung (7207214), Haein Kim (4839594), Joo-Yeon Lee (8816642), Young Ho Lee (7851581), Sun Young Cho (8768878), Byoung Kwon Park (6740516), Kyungmin Huh (5636111), Kyong Ran Peck (8768880), Jae-Hoon Ko (6800930), Yoo Jin Na (4002788), Jung-Min Lee (546902), Jeong-Sun Yang (4856530), Sehee Park (521956), Hyungjin Kim (582645), Jinyoung Yang (1692094), Myungsun Lee (384428), Younmin Shin (13945449), Jun-Won Kim (13407875), Cheol-In Kang (6800951)   +18 more
core   +1 more source

Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19

, 2023
Nirmatrelvir/ritonavir (Paxlovid) consists of a peptidomimetic inhibitor (nirmatrelvir) of the SARS-CoV-2 main protease and a pharmacokinetic enhancer (ritonavir). It is approved for the treatment of mild-to-moderate COVID-19.
Lawson, R., Lemaitre, F., Johnson-Davis, K.L., Langman, L.J., Bergan, S., Budde, K., Gelder, T. van, Pattanaik, S., Noceti, O., Pawinski, T., Hesselink, D.A., Masuda, S., Moes, D.J.A.R., Elens, L., Winter, B.C.M. de, Brunet, M., Venkataramanan, R.   +16 more
core   +2 more sources

Extending the Targets for Coronavirus Antivirals Beyond That of Approved Drugs: Insights From Preclinical Research

Microbial Biotechnology, Volume 19, Issue 5, May 2026.
Chemical structure of RIBOTAC inhibitor with metabolic handle binding as nucleotide analogue to SARS‐CoV‐2 RNA dependent RNA polymerase, its linker and the RNase L recruiter which binds RNase L monomers and mediates their dimerization that actives nuclease activity degrading the viral RNA.
Harald Brüssow
wiley   +1 more source

Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study [PDF]

Osong Public Health and Research Perspectives
Objectives This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and older.
Dong-Hwi Kim, Min-Gyu Yoo, Na-Young Kim, So Young Choi, Minjeong Jang, Misuk An, Se-Jin Jeong, Jungyeon Kim   +7 more
doaj   +1 more source

Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19

SAGE Open Medical Case Reports, 2023
COVID-19 emerged in 2019 and was declared a pandemic by the World Health Organization in March 2020. COVID-19 is highly transmissible and can lead to bilateral pneumonia with severe respiratory failure.
Elizabeth DeMarco, Matthew Turnipseed, Brian Clarke, Farhan Qadeer   +3 more
doaj   +1 more source

Nirmatrelvir-ritonavir for COVID-19 [PDF]

Canadian Medical Association Journal, 2022
McDonald, Emily G, Lee, Todd C
openaire   +2 more sources

“Nirmatrelvir/ritonavir as a posible treatment for Long-COVID ”

, 2023
It is estimated that about 10% of patients who have been infected with SARS-CoV-2 worldwide suffer from Long-Covid, about 65 million people [1]. Although we are beginning to know its pathophysiology, there is still no evidence on its treatment.
-Ignacio Pérez Catalán, Adriana Gascon Buj, -Sergio García Muñoz, -Iris Gómez Alfaro, -Celia Roig Martí, -Miguel Torres García, -Roberto Reig Valero, -Raúl Ferrando Piqueres, -Lidón Mateu Campos, Jose-Manuel Ramos, -Jorge Usó Blasco   +10 more
openaire   +2 more sources